Data Insights

CTX-112 by CRISPR Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval

CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-112 in Marginal Zone B-cell Lymphoma

Data Insights

CTX-112 by CRISPR Therapeutics for B-Cell Chronic Lymphocytic Leukemia: Likelihood of Approval

CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-112 in B-Cell Chronic Lymphocytic Leukemia

Data Insights

CTX-112 by CRISPR Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-112 in B-Cell Non-Hodgkin Lymphoma

Data Insights

CTX-112 by CRISPR Therapeutics for Follicular Lymphoma: Likelihood of Approval

CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-112 in Follicular Lymphoma

Data Insights

CTX-112 by CRISPR Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval

CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-112 in Mantle Cell Lymphoma

Data Insights

CTX-112 by CRISPR Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-112 in Diffuse Large B-Cell Lymphoma

Data Insights

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoFH): Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Homozygous Familial Hypercholesterolemia (HoFH). According to...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-310 in Homozygous Familial Hypercholesterolemia (HoFH)

Data Insights

CTX-310 by CRISPR Therapeutics for Heterozygous familial hypercholesterolemia (heFH): Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH). According to...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-310 in Heterozygous familial hypercholesterolemia (heFH)

Data Insights

CTX-110 by CRISPR Therapeutics for Follicular Lymphoma: Likelihood of Approval

CTX-110 is under clinical development by CRISPR Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-110 in Follicular Lymphoma

Data Insights

CTX-110 by CRISPR Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

CTX-110 is under clinical development by CRISPR Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-110 in Diffuse Large B-Cell Lymphoma

Data Insights

CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-310 in Hypertriglyceridemia

Data Insights

CTX-320 by CRISPR Therapeutics for Atherosclerosis: Likelihood of Approval

CTX-320 is under clinical development by CRISPR Therapeutics and currently in Phase I for Atherosclerosis. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-320 in Atherosclerosis

Data Insights

CTX-110 by CRISPR Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

CTX-110 is under clinical development by CRISPR Therapeutics and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-110 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Exagamglogene autotemcel by CRISPR Therapeutics for Sickle Cell Disease: Likelihood of Approval

Exagamglogene autotemcel is under clinical development by CRISPR Therapeutics and currently in Phase III for Sickle Cell Disease. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Exagamglogene Autotemcel in Sickle Cell Disease

Data Insights

CTX-310 by CRISPR Therapeutics for Mixed Dyslipidemia: Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Mixed Dyslipidemia. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-310 in Mixed Dyslipidemia

Data Insights

Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics's CTX-112?

CTX-112 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Marginal Zone B-cell...

Net Present Value Model: CRISPR Therapeutics AG's CTX-112

Data Insights

Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics's CTX-130?

CTX-130 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase I program in T-Cell Lymphomas. According...

Net Present Value Model: CRISPR Therapeutics AG's CTX-130

Data Insights

CTX-120 by CRISPR Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval

CTX-120 is under clinical development by CRISPR Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-120 in Refractory Multiple Myeloma

Data Insights

CTX-120 by CRISPR Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval

CTX-120 is under clinical development by CRISPR Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-120 in Relapsed Multiple Myeloma